Antiretroviral treatment in 1998. (Q43890540)

27 November 2017

1 reference

title

Antiretroviral treatment in 1998. (English)

1 reference

27 November 2017

2

R Hogg

1 reference

27 November 2017

J S Montaner

1

1 reference

27 November 2017

J Raboud

series ordinal

3

1 reference

27 November 2017

R Harrigan

series ordinal

4

1 reference

27 November 2017

M O'Shaughnessy

series ordinal

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

27 November 2017

1 reference

27 November 2017

volume

352

1 reference

27 November 2017

issue

9144

1 reference

27 November 2017

page(s)

1919-1922

1 reference

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Decline in deaths from AIDS due to new antiretrovirals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Rebound of plasma HIV viral load following prolonged suppression with combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

The era of adherence to HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

HIV/AIDS treatment: lessons from the tuberculosis experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

One world, one hope: the cost of providing antiretroviral therapy to all nations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907532-1

7 January 2021

10.1016/S0140-6736(98)07532-1

Identifiers

DOI

1 reference

27 November 2017

1 reference